Lilly's Lohmann acquisition pays off for Elanco; IDEXX charts sales growth in companion animal products;

> Eli Lilly ($LLY) reported that sales in its Elanco animal health division grew 10% in the third quarter to $585 million, due partly to its acquisition of Lohmann. Release

> IDEXX Laboratories saw revenues in its companion animal division grow 13% in the third quarter to $321 million. Release

> Diagnostics maker Abaxis ($ABAX) reported record second-quarter revenues of $53.9 million, largely thanks to its veterinary service sales, which rose 50% year-over-year. Release

> The U.K.'s Animalcare Group reported that sales in the year ended June 30, 2014, rose 6% to £12.9 million ($20.5 million) and profits were up slightly to 2.8 million pounds ($4.5 million). Release (PDF)

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…